Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Controlled release pharmaceutical compositions comprising a fumaric acid ester

a technology of controlled release and pharmaceutical compositions, which is applied in the direction of botany apparatus and processes, pharmaceuticals, applications, etc., can solve the problems that fumarate therapy like e.g. fumaderm® often gives rise to gastro-intestinal side effects, and achieves the effects of reducing dependence, prolonging time period, and reducing interindividual and/or intraindividual variation in plasma profiles

Inactive Publication Date: 2013-11-28
BIOGEN SWISS MFG GMBH
View PDF2 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The controlled release composition significantly reduces gastrointestinal side effects and improves therapeutic efficacy by maintaining effective plasma concentrations for longer periods, potentially requiring fewer doses and enhancing patient comfort.

Problems solved by technology

However, therapy with fumarates like e.g. Fumaderm® frequently gives rise to gastro-intestinal side effects such as e.g. fullness, diarrhea, upper abdominal cramps, flatulence and nausea.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Controlled release pharmaceutical compositions comprising a fumaric acid ester
  • Controlled release pharmaceutical compositions comprising a fumaric acid ester
  • Controlled release pharmaceutical compositions comprising a fumaric acid ester

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Tablets

[0169]200 g granules are mixed with 150 g microcrystalline cellulose (e.g. Avicel® 102), 97.5 g lactose (e.g. Tablettose®), 10 g sodium carboxymethylcellulose (e.g. Ac-Di-Sol®) and 25 g starch for 30 min. Then 10 g magnesium stearate and 7.5 g amorphous silicium dioxide (e.g. Aerosil® 200) is added and the powder mixture is mixed for 5 min.

[0170]This powder mixture is compressed to tablets in tabletting equipment (tablet diameter 10 mm, surface about 280-300 mm2). The tablets are enteric coated in a pan-coating or in a fluid-bed coating process as described in Example 4.

example 2

Preparation of Tablets

[0171]200 g micro-crystals are mixed with 150 g microcrystalline cellulose (e.g. Avicel® 102), 130 g lactose (e.g. Tablettose®), 10 g of sodium carboxymethylcellulose (e.g. Ac-Di-Son and 25 mg starch for 30 min. Then 10 g magnesium stearate and 7.5 g of amorphous silicium dioxide is added and the powder mixture is mixed for 5 min. This powder mixture is compressed to tablets in tabletting equipment (tablet diameter 10 mm, surface about 280-300 mm2). The tablets are enteric coated in a pan-coating or in a fluid-bed coating process as described in Example 4.

example 3

Preparation of Capsules

[0172]Granules or micro-crystals are filled in HPMC capsules and these capsules are enteric coated as described in the following. In a pan coater Eudragit® L30D-55 is sprayed at drying temperatures of 60° C. to 80° C. onto the capsules in an amount of 20 mg polymeric material per mm2. Pigments and talc are added in an appropriate amount.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The invention features a kit. The kit includes: (i) a first unit dosage form consisting essentially of about 120 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release; and (ii) a second unit dosage form consisting essentially of about 240 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release.

Description

FIELD OF THE INVENTION[0001]The present invention relates to controlled release pharmaceutical compositions comprising a fumaric acid ester as an active substance. The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.BACKGROUND OF THE INVENTION[0002]Fumaric acid esters, i.e. dimethylfumarate in combination with ethylhydrogenfumarat have been used in the treatment of psoriasis for many years. The combination is marketed under the tradename Fumaderm®. It is in the form of tablets intended for oral use and it is available in two different dosage strengths (Fumaderm® initial and Fumaderm®):Fumaderm ® InitialFumaderm ®Dimethy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/225A61K9/50A61K9/28
CPCA61K31/225A61K9/28A61K9/50A61K45/06A61K9/2013A61K9/2027A61K9/2054A61K9/2846A61K9/4891A61K31/215A61K31/22A61K9/2853A61K9/2866A61K9/2031A61K9/2077A61K9/2081A61K9/4808A61P1/04A61P1/16A61P17/00A61P17/06A61P19/02A61P25/00A61P25/04A61P29/00A61P35/00A61P37/00A61P37/02A61P37/06A61P43/00A61P5/14A61P7/06A61P3/10A61K2300/00A61K9/5042A61K9/5047A61K9/5084A61K9/14A61K9/167A61K9/20A61K9/48A61K9/0053
Inventor NILSSON, HENRIKSCHONHARTING, FLORIANMULLER, BERND W.ROBINSON, JOSEPH R.
Owner BIOGEN SWISS MFG GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com